Skip to main content

Advertisement

SpringerLink
Log in

Burden and cost of hospital admissions for vaccine-preventable paediatric pneumococcal disease and non-typable Haemophilus influenzae otitis media in New Zealand

  • Original Research Article
  • Published:
Applied Health Economics and Health Policy Aims and scope Submit manuscript

Abstract

Introduction

Streptococcus pneumoniae (Sp.) is a leading cause of paediatric bacterial meningitis, pneumonia and acute otitis media, as is non-typable Haemophilus influenzae (NTHi) for acute otitis media. In 2008, a 7-valent conjugated pneumococcal vaccine (PCV7) was included in the New Zealand (NZ) childhood immunization schedule.

Objective

To estimate the potentially vaccine-preventable annual hospital admissions and cost to the NZ Government of paediatric admissions for pneumococcal disease and NTHi otitis media prior to the immunization programme.

Methods

Admissions (2000–7) and deaths (2000–5) in children aged <20 years with pneumococcal meningitis or bacteraemia, pneumonia or otitis media were identified in national datasets and linked by unique patient identifiers. New episodes of illness were defined as admissions occurring >30 days after discharge from a previous admission. Informed by the literature, pneumococcal pneumonia episodes were estimated at 33% of all-cause pneumonia admissions; Sp. and NTHi otitis media episodes were estimated jointly at 72% of otitis media admissions. Each episode was assigned a single diagnosis according to the following hierarchy: meningitis > bacteraemia > pneumonia > otitis media. Incidence rates for episodes were determined for 2000–7 (meningitis, bacteraemia and pneumonia) and 2006–7 (otitis media). Annual DRG-based costs for pneumococcal meningitis, bacteraemia, pneumonia and otitis media were estimated as (episode rate) × (DRG cost weight per episode) × (2007 population) × (national price per cost weight).

Results

Episode rates for pneumococcal meningitis, bacteraemia and pneumonia were stable in 2000–7, highest in the second 6 months of life and declined steeply over the first 5 years of life. Mean rates per 100 000 in 2000–7 were 18.4, 27.6 and 464 for pneumococcal meningitis, bacteraemia and pneumonia, respectively, for children aged <2 years; 8.4, 14.9 and 295 for children aged <5 years (including those aged <2 years); and 2.2, 4.4 and 97 for children aged <20 years (including those aged <5 years). Mean rates per 100 000 in 2006–7 for Sp. and NTHi otitis media combined were 631 (surgical) and 197 (medical) for children aged <2 years; 691 and 116 for children aged <5 years; and 281 and 35 for children aged <20 years. Pacific Island and indigenous Māori children generally had higher rates than European/other children. Rates increased with socioeconomic disadvantage, across all diagnoses. The annual cost to Government of pneumococcal disease and NTHi otitis media admissions for children aged <20 years was estimated at New Zealand dollars ($NZ)9.95 million (range 7.7–12.2 million) [about $US7.1 million]. Most of this cost was shared between pneumococcal pneumonia (48%) and otitis media (45%), and 78% was incurred in the first 2 years of life. Estimated annual paediatric mortality rates per 100 000 for children aged <5 years were 0.48, 0.30 and 0.54 for pneumococcal meningitis, bacteraemia and pneumonia, respectively. The analysis predicted four or five pneumococcal deaths per year (range 1–8) for children aged <5 years.

Conclusions

Prior to the introduction of a national Sp. immunization programme, hospital admissions for Sp. disease and NTHi otitis media in NZ cost about $NZ10 million annually, mostly for children aged <2 years and particularly for those living in relative socioeconomic deprivation and for Pacific Island and Māori children. There were about five pneumococcal deaths annually. With adjustment for local serotypes, vaccine serotype coverage and uptake, immunization with any of the three available pneumococcal vaccines would reduce this burden substantially.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1
Fig. 2
Table III
Table IV
Fig. 3
Table V
Table VI

Similar content being viewed by others

References

  1. Melegaro A, Edmunds WJ, Pebody R, et al. The current burden of pneumococcal disease in England and Wales. J Infect 2006 Jan; 52(1): 37–48

    Article  PubMed  CAS  Google Scholar 

  2. Robinson KA, Baughman W, Rothrock G, et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995–1998: opportunities for prevention in the conjugate vaccine era. JAMA 2001 Apr 4; 285(13): 1729–35

    Article  PubMed  CAS  Google Scholar 

  3. Cartwright K. Pneumococcal disease in western Europe: burden of disease, antibiotic resistance and management. Eur J Pediatr 2002 Apr; 161(4): 188–95

    Article  PubMed  CAS  Google Scholar 

  4. Poehling KA, Talbot TR, Griffin MR, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 2006 Apr 12; 295(14): 1668–74

    Article  PubMed  CAS  Google Scholar 

  5. Roche PW, Krause V, Cook H, et al. Invasive pneumococcal disease in Australia, 2006. Commun Dis Intell 2008 Mar; 32(1): 18–30

    Google Scholar 

  6. Winters M, Patrick DM, Marra F, et al. Epidemiology of invasive pneumococcal disease in BC during the introduction of conjugated pneumococcal vaccine. Can J Public Health 2008 Jan-Feb; 99(1): 57–61

    PubMed  Google Scholar 

  7. Pavia M, Bianco A, Nobile CG, et al. Efficacy of pneumococcal vaccination in children younger than 24 months: a meta-analysis. Paediatrics 2009 Jun; 123(6): e1103–10

    Article  Google Scholar 

  8. Dinleyici EC, Yargic ZA. Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine. Exp Rev Vaccines 2009 Aug; 8(8): 977–86

    Article  CAS  Google Scholar 

  9. Schuerman L, Borys D, Hoet B, et al. Prevention of otitis media: now a reality? Vaccine 2009 25; 27(42): 5748–54

    Article  PubMed  CAS  Google Scholar 

  10. Prymula R, Peeters P, Chrobok V, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006 Mar 4; 367(9512): 740–8

    Article  PubMed  CAS  Google Scholar 

  11. WHO. Pneumococcal vaccines: WHO position paper. Wkly Epidemiol Rec 1999; 74: 177–84

    Google Scholar 

  12. Heffernan HM, Martin DR, Woodhouse RE, et al. Invasive pneumococcal disease in New Zealand 1998–2005: capsular serotypes and antimicrobial resistance. Epidemiol Infect 2008 Mar; 136(3): 352–9

    Article  PubMed  CAS  Google Scholar 

  13. Voss L, Lennon D, Okesene-Gafa K, et al. Invasive pneumococcal disease in a paediatric population, Auckland, New Zealand. Pediatr Infect Dis J 1994 Oct; 13(10): 873–8

    Article  PubMed  CAS  Google Scholar 

  14. Ortqvist A, Hedlund J, Kalin M. Streptococcus pneumoniae: epidemiology, risk factors, and clinical features. Semin Respir Crit Care Med 2005 Dec; 26(6): 563–74

    Article  PubMed  Google Scholar 

  15. Levine OS, O’Brien KL, Knoll M, et al. Pneumococcal vaccination in developing countries. Lancet 2006 Jun 10; 367(9526): 1880–2

    Article  PubMed  Google Scholar 

  16. Craig E, Jackson C, Han D, et al. Monitoring the health of New Zealand children and young people. Auckland: Paediatric Society of New Zealand, New Zealand Child and Youth Epidemiology Service, 2007

    Google Scholar 

  17. O’Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009 12; 374(9693): 893–902

    Article  PubMed  Google Scholar 

  18. Centers for Disease Control and Prevention. Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine-United States, 1997–2006. MMWR Morb Mort Wkly Rep 2009 Jan 16; 58(1): 1–4

    Google Scholar 

  19. Hausdorff WP, Dagan R. Serotypes and pathogens in paediatric pneumonia. Vaccine 2008 16; 26(Suppl. 2): B19–23

    Article  PubMed  Google Scholar 

  20. Morris PS, Leach AJ. Acute and chronic otitis media. Paediatr Clin North Am 2009 Dec; 56(6): 1383–99

    Article  Google Scholar 

  21. Leibovitz E, Jacobs MR, Dagan R. Haemophilus influenzae: a significant pathogen in acute otitis media. Paediatr Infect Dis J 2004 Dec; 23(12): 1142–52

    Google Scholar 

  22. Rosenblut A, Santolaya ME, Gonzalez P, et al. Bacterial and viral etiology of acute otitis media in Chilean children. Pediatr Infect Dis J 2001 May; 20(5): 501–7

    Article  PubMed  CAS  Google Scholar 

  23. Casey JR, Pichichero ME. Changes in frequency and pathogens causing acute otitis media in 1995–2003. Pediatr Infect Dis J 2004 Sep; 23(9): 824–8

    Article  PubMed  Google Scholar 

  24. Morris PS, Leach AJ, Halpin S, et al. An overview of acute otitis media in Australian Aboriginal children living in remote communities. Vaccine 2007 Mar 22; 25(13): 2389–93

    Article  PubMed  CAS  Google Scholar 

  25. Leibovitz E, Satran R, Piglansky L, et al. Can acute otitis media caused by Haemophilus influenzae be distinguished from that caused by Streptococcus pneumoniae? Pediatr Infect Dis J 2003 Jun; 22(6): 509–15

    PubMed  Google Scholar 

  26. Ministry of Health. Immunisation handbook. Wellington: Ministry of Health, 2006

    Google Scholar 

  27. Palmu A, Jokinen J, Kilpi T, et al. Impact of different case definitions for acute otitis media on the efficacy estimates of a pneumococcal conjugate vaccine. Vaccine 2008 12; 26(20): 2466–70

    Article  PubMed  CAS  Google Scholar 

  28. Plasschaert AI, Rovers MM, Schilder AG, et al. Trends in doctor consultations, antibiotic prescription, and specialist referrals for otitis media in children: 1995–2003. Paediatrics 2006 Jun; 117(6): 1879–86

    Article  Google Scholar 

  29. Ray GT, Whitney CG, Fireman BH, et al. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr Infect Dis J 2006 Jun; 25(6): 494–501

    Article  PubMed  Google Scholar 

  30. Morrow A, De Wals P, Petit G, et al. The burden of pneumococcal disease in the Canadian population before routine use of the seven-valent pneumococcal conjugate vaccine. Can J Infect Dis Med Microbiol 2007 May; 18(2): 121–7

    PubMed  Google Scholar 

  31. Fireman B, Black SB, Shinefield HR, et al. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J 2003 Jan; 22(1): 10–6

    Article  PubMed  Google Scholar 

  32. Greville Consulting. New Zealand vision and hearing screening report July 2005–June 2006. Auckland: National Audiology Centre, 2006

    Google Scholar 

  33. Palmu AA, Verho J, Jokinen J, et al. The seven-valent pneumococcal conjugate vaccine reduces tympanostomy tube placement in children. Pediatr Infect Dis J 2004 Aug; 23(8): 732–8

    Article  PubMed  Google Scholar 

  34. Jardine A, Menzies RI, Deeks SL, et al. The impact of pneumococcal conjugate vaccine on rates of myringotomy with ventilation tube insertion in Australia. Pediatr Infect Dis J 2009 Sep; 28(9): 761–5

    Article  PubMed  Google Scholar 

  35. World Health Organization. International statistical classification of diseases and related health problems, 10th revision, version for 2007: tabular list of inclusions and four-character subcategories [online]. Available from URL: http://apps.who.int/classifications/apps/icd/icd10online/ [Accessed 2010 Jul 22]

  36. Giorgi Rossi P, Agabiti N, Faustini A, et al. The burden of hospitalised pneumonia in Lazio, Italy, 1997–1999. Int J Tuberc Lung Dis 2004 May; 8(5): 528–36

    Google Scholar 

  37. Dagan R. Pneumococcal conjugate vaccines probe studies: the solution points to the problem. Adv Exp Med Biol 2009; 634: 69–77

    Article  PubMed  Google Scholar 

  38. Jackson CJ, Lennon D, Heffernan H, et al. Estimating invasive pneumococcal disease burden in New Zealand children: comparison of hospitalisation data with active and passive surveillance data. 7th International Symposium on Pneumococci and Pneumococcal Paediatric Diseases; 2010 Mar 14–18; Tel Aviv

    Google Scholar 

  39. Barkai G, Leibovitz E, Givon-Lavi N, et al. Potential contribution by nontypable Haemophilus influenzae in protracted and recurrent acute otitis media. Paediatr Infect Dis J 2009 Jun; 28(6): 466–71

    Article  Google Scholar 

  40. Salmond C, Crampton P, Atkinson J. NZDep2006: index of deprivation 2007. Wellington: Department of Public Health, Wellington School of Medicine and Health Sciences, 2007 [online]. Available from URL: http://www.uow.otago.ac.nz/academic/dph/research/NZDep/NZDep2006%20research%20report%2004%20September%202007.pdf [Accessed 2010 Jul 22]

    Google Scholar 

  41. Statistics New Zealand [online]. Available from URL: http://www.stats.govt.nz/ [Accessed 2010 Jul 22]

  42. Zhou F, Kyaw MH, Shefer A, et al. Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. Arch Pediatr Adolesc Med 2007 Dec; 161(12): 1162–8

    Article  PubMed  Google Scholar 

  43. Jefferson T, Ferroni E, Curtale F, et al. Streptococcus pneumoniae in western Europe: serotype distribution and incidence in children less than 2 years of age. Lancet Infect Dis 2006 Jul; 6(7): 405–10

    Article  PubMed  Google Scholar 

  44. Petit G, De Wals P, Law B, et al. Epidemiological and economic burden of pneumococcal diseases in Canadian children. Can J Infect Dis 2003 Jul; 14(4): 215–20

    PubMed  Google Scholar 

  45. Salleras L, Dominguez A. Streptococcus pneumoniae incidence in western Europe. Lancet Infect Dis 2007 Apr; 7(4): 242–3

    Article  PubMed  Google Scholar 

  46. Leibovitz E, Greenberg D. Acute otitis media in children: current epidemiology, microbiology, clinical manifestations, and treatment. Chang Gung Med J 2004 Jul; 27(7): 475–88

    PubMed  Google Scholar 

  47. Grant C, Milne R. What does pneumonia cost New Zealand? In: Asher I, Byrnes C, editors. Catching our breath. Auckland: Paediatric Society of New Zealand, 2006: 12–3

    Google Scholar 

  48. Grant CC, Scragg R, Tan D, et al. Hospitalization for pneumonia in children in Auckland, New Zealand. J Paediatr Child Health 1998 Aug; 34(4): 355–9

    Article  PubMed  CAS  Google Scholar 

  49. Payne SM, Donahue C, Rappo P, et al. Variations in paediatric pneumonia and bronchitis/asthma admission rates. Arch Pediatr Adolesc Med 1995 Feb; 149(2): 162–9

    Article  PubMed  CAS  Google Scholar 

  50. Rudan I, Boschi-Pinto C, Biloglav Z, et al. Epidemiology and etiology of childhood pneumonia. Bull World Health Organ 2008 May; 86(5): 408–16

    Article  PubMed  Google Scholar 

  51. Giles M, Asher I. Prevalence and natural history of otitis media with perforation in Maori school children. J Laryngol Otol 1991 Apr; 105(4): 257–60

    Article  PubMed  CAS  Google Scholar 

  52. Giles M, O’Brien P. The prevalence of hearing impairment amongst Maori schoolchildren. Clin Otolaryngol Allied Sci 1991 Apr; 16(2): 174–8

    Article  PubMed  CAS  Google Scholar 

  53. Giles M, O’Brien P. Otitis media and hearing loss in the children of the Ruatoki valley: a continuing public health problem. N Z Med J 1989 12; 102(865): 160–1

    PubMed  CAS  Google Scholar 

  54. Ministry of Health. Immunisation coverage: national and DHB data [online]. Available from URL: http://www.moh.govt.nz/moh.nsf/indexmh/immunisation-coverage-data [Accessed 2010 Jul 22]

  55. Djuretic T, Ryan MJ, Miller E, et al. Hospital admissions in children due to pneumococcal pneumonia in England. J Infect 1998 Jul; 37(1): 54–8

    Article  PubMed  CAS  Google Scholar 

  56. Hansen J, Black S, Shinefield H, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Paediatr Infect Dis J 2006 Sep; 25(9): 779–81

    Article  Google Scholar 

  57. LeBas SJ, Grier LR, Campbell GD, et al. Nosocomial pneumonia. Curr Opin Pulm Med 1996 May; 2(3): 206–12

    Article  PubMed  CAS  Google Scholar 

  58. Cutts FT, Zaman SM, Enwere G, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005 Mar 26-Apr 1; 365(9465): 1139–46

    Article  PubMed  CAS  Google Scholar 

  59. Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003 Oct 2; 349(14): 1341–8

    Article  PubMed  CAS  Google Scholar 

  60. Madhi SA, Kuwanda L, Cutland C, et al. The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children. Clin Infect Dis 2005 15; 40(10): 1511–8

    Article  PubMed  Google Scholar 

  61. Watt JP, Wolfson LJ, O’Brien KL, et al. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet 2009 12; 374(9693): 903–11

    Article  PubMed  Google Scholar 

  62. Murdoch DR, Laing RT, Mills GD, et al. Evaluation of a rapid immunochromatographic test for detection of Streptococcus pneumoniae antigen in urine samples from adults with community-acquired pneumonia. J Clin Microbiol 2001 Oct; 39(10): 3495–8

    Article  PubMed  CAS  Google Scholar 

  63. Grijalva CG, Nuorti JP, Arbogast PG, et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007; 369(9568): 1179–86

    Article  PubMed  CAS  Google Scholar 

  64. Mackenzie GA, Carapetis JR, Morris PS, et al. Current issues regarding the use of pneumococcal conjugate and polysaccharide vaccines in Australian children. J Paediatr Child Health 2005 Apr; 41(4): 201–8

    Article  PubMed  Google Scholar 

  65. Teele DW, Klein JO, Rosner B. Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study. J Infect Dis 1989 Jul; 160(1): 83–94

    Article  PubMed  CAS  Google Scholar 

  66. Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine 2004 22; 22(31-32): 4203–14

    Article  PubMed  CAS  Google Scholar 

  67. Jansen A. Pneumococcal infection in preschool children: incidence of acute otitis media and pneumonia related to influenza and respiratory syncytila virus circulation [abstract]. Presented at the ISPPD 5th International Symposium on Pneumococci and Pneumococcal Diseases; 2006 Apr 2–6; Alice Springs (NT)

  68. Caceres Udina MJ, Varez Martinez JA, Chumilla Valderas MA, et al. Incidence, air pollution and risk factors of acute otitis media in the first year of life: a prospective study. An Pediatr (Barc) 2004; 60: 133–8

    Article  Google Scholar 

  69. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001 8; 344(6): 403–9

    Article  PubMed  CAS  Google Scholar 

  70. Milne RJ, Grimwood K. Budget impact and cost-effectiveness of including a pentavalent rotavirus vaccine in the New Zealand childhood immunisation schedule. Value Health 2009 Sep; 12(6): 888–98

    Article  PubMed  Google Scholar 

  71. Bedford H, de Louvois J, Halket S, et al. Meningitis in infancy in England and Wales: follow up at age 5 years. BMJ 2001 8; 323(dy7312): 533–6

    Article  PubMed  CAS  Google Scholar 

  72. Ministry of Health. Discharges from privately funded hospitals: 1 July 2004 to 30 June 2005 [online]. Available from URL: http://www.moh.govt.nz/moh.nsf/indexmh/discharges-privately-funded-hospitals-0405-nov09 [Accessed 2010 Jul 22]

  73. Grijalva CG, Griffin MR. Population-based impact of routine infant immunisation with pneumococcal conjugate vaccine in the USA. Exp Rev Vaccines 2008 Feb; 7(1): 83–95

    Article  Google Scholar 

  74. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of proteinpolysaccharide conjugate vaccine. N Engl J Med 2003 1; 348(18): 1737–46

    Article  PubMed  Google Scholar 

  75. Zhou F, Shefer A, Kong Y, et al. Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997–2004. Paediatrics 2008 Feb; 121(2): 253–60

    Article  Google Scholar 

  76. Grijalva CG. Recognising pneumonia burden through prevention. Vaccine 2009 21; 27(Suppl. 3): C6–8

    Article  PubMed  Google Scholar 

  77. Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of paediatric pneumococcal conjugate vaccine. JAMA 2005 Oct 26; 294(16): 2043–51

    Article  PubMed  CAS  Google Scholar 

  78. Centers for Disease Control (CDC). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal vaccine on incidence of invasive pneumococcal disease: United States, 1998–2003. MMWR Morb Mortal Wkly Rep 2005; 54: 893–7

    Google Scholar 

  79. Grijalva CG, Poehling KA, Nuorti JP, et al. National impact of universal childhood immunisation with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Paediatrics 2006 Sep; 118(3): 865–73

    Article  Google Scholar 

  80. Shafinoori S, Ginocchio CC, Greenberg AJ, et al. Impact of pneumococcal conjugate vaccine and the severity of winter influenza-like illnesses on invasive pneumococcal infections in children and adults. Paediatr Infect Dis J 2005 Jan; 24(1): 10–6

    Article  Google Scholar 

  81. Nelson JC, Jackson M, Yu O, et al. Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults. Vaccine 2008; 26(38): 4947–54

    Article  PubMed  Google Scholar 

  82. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group [comment]. Paediatr Infect Dis J 2000; 19(3): 187–95

    Article  CAS  Google Scholar 

  83. Black S, Shinefield H. Safety and efficacy of the seven-valent pneumococcal conjugate vaccine: evidence from Northern California. Eur J Pediatr 2002 Dec; 161Suppl. 2: S127–31

    Article  PubMed  Google Scholar 

  84. Shinefield H, Black S, Ray P, et al. Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants. Paediatr Infect Dis J 2002 Mar; 21(3): 182–6

    Article  Google Scholar 

  85. Croxtall JD, Keating GM. Pneumococcal polysaccharide protein D-conjugate vaccine (Synflorix; PHiD-CV). Paediatr Drugs 2009; 11(5): 349–57.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Chris Lewis from the NZ Health Information Service of the Ministry of Health provided mortality datasets and hospital admissions with DRG cost weights. Lesley Salkeld (Star-ship Children’s Health), Josie Whittaker (Auckland Hospital) and Christine Forster (Ministry of Health) advised on disease coding. Keith Grimwood (Queensland Children’s Medical Research Institute) reviewed the manuscript. The authors thank three anonymous reviewers for their helpful comments.

This study was funded by GlaxoSmithKline (NZ) Ltd. The sponsor reviewed the manuscript but took no part in study design, analysis or interpretation of the findings.

The authors have no conflicts of interest.

Author information

Authors and Affiliations

  1. School of Population Health, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand

    Richard J. Milne (Associate Professor)

  2. Department of Statistics, University of Auckland, Auckland, New Zealand

    Stephen Vander Hoorn

Authors
  1. Richard J. Milne
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen Vander Hoorn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard J. Milne.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Milne, R.J., Vander Hoorn, S. Burden and cost of hospital admissions for vaccine-preventable paediatric pneumococcal disease and non-typable Haemophilus influenzae otitis media in New Zealand. Appl Health Econ Health Policy 8, 281–300 (2010). https://doi.org/10.2165/11535710-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11535710-000000000-00000

Keywords

Search

Navigation